Akihiko Sekizawa

List of Publications by Year in Descending Order

111 papers	2,944 citations	31 h-index	50 g-index
117 ext. papers	3,327 ext. citations	3.4 avg, IF	4.41 L-index

#	Paper	IF	Citations
111	Antimicrobial Resistance for Genital Infection during Pregnancy in Japan.. *Infection and Chemotherapy*, **2022**, 54, 173-175	3.9	
110	Medical Professional Enhancement Using Explainable Artificial Intelligence in Fetal Cardiac Ultrasound Screening.. *Biomedicines*, **2022**, 10,	4.8	7
109	Predictive ability of serum advanced glycation end products at 11 to 13 weeks of gestation for early-onset preeclampsia. *AJOG Global Reports*, **2022**, 2, 100052		
108	Prenatal Identification of Confined Placental Mosaicism in Pregnant Women with Fetal Growth Restriction. *Reproductive Sciences*, **2021**, 1	3	
107	Infective endocarditis due to Streptococcus agalactiae in the puerperal period. *Journal of Obstetrics and Gynaecology Research*, **2021**, 47, 2238-2241	1.9	0
106	Tadalafil treatment for preeclampsia (medication in preeclampsia; MIE): a multicenter phase II clinical trial. *Journal of Maternal-Fetal and Neonatal Medicine*, **2021**, 34, 3709-3715	2	4
105	Accuracy of the FMF Bayes theorem-based model for predicting preeclampsia at 11-13 weeks of gestation in a Japanese population. *Hypertension Research*, **2021**, 44, 685-691	4.7	4
104	Postpartum questionnaire survey of women who tested negative in a non-invasive prenatal testing: examining negative emotions towards the test. *Journal of Human Genetics*, **2021**, 66, 579-584	4.3	0
103	Retrospective details of false-positive and false-negative results in non-invasive prenatal testing for fetal trisomies 21, 18 and 13. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2021**, 256, 75-81	2.4	7
102	Shadow Estimation for Ultrasound Images Using Auto-Encoding Structures and Synthetic Shadows. *Applied Sciences (Switzerland)*, **2021**, 11, 1127	2.6	11
101	The routine use of prophylactic Bakri balloon tamponade contributes to blood loss control in major placenta previa. *International Journal of Gynecology and Obstetrics*, **2021**, 154, 508-514	4	3
100	Examination of clinical factors affecting intrauterine microbiota.. *Reproduction and Fertility*, **2021**, 2, 1-6	1.1	1
99	Evaluation of the clinical performance of noninvasive prenatal testing at a Japanese laboratory. *Journal of Obstetrics and Gynaecology Research*, **2021**, 47, 3437-3446	1.9	0
98	Detection of Cardiac Structural Abnormalities in Fetal Ultrasound Videos Using Deep Learning. *Applied Sciences (Switzerland)*, **2021**, 11, 371	2.6	21
97	Assessment of the value of measuring soluble fms-like tyrosine kinase-1 and placental growth factor levels following administration of tadalafil to treat fetal growth restriction.. *Journal of Maternal-Fetal and Neonatal Medicine*, **2021**, 1-5	2	
96	Next-Generation Sequencing Reveals Downregulation of the Wnt Signaling Pathway in Human Dysmature Cumulus Cells as a Hallmark for Evaluating Oocyte Quality. *Reproductive Medicine*, **2020**, 1, 205-215	0.5	1
95	Declined use of cervical ripening balloon did not reduce the incidence of umbilical cord prolapse in Japan. *Journal of Obstetrics and Gynaecology Research*, **2020**, 46, 1349-1354	1.9	1

94	Successful monozygotic triplet pregnancy after a single blastocyst transfer following in vitro maturation of oocytes from a woman with polycystic ovary syndrome: a case report. *BMC Pregnancy and Childbirth*, **2020**, 20, 57	3.2	3
93	Three-Dimensional Peripheral Bloodstream Model of the Uterus for Laparoscopic Radical Hysterectomy. *Journal of Minimally Invasive Gynecology*, **2020**, 27, 1196-1202	2.2	
92	Image Segmentation of the Ventricular Septum in Fetal Cardiac Ultrasound Videos Based on Deep Learning Using Time-Series Information. *Biomolecules*, **2020**, 10,	5.9	20
91	Successful Pregnancy in a Case of Behçet's Disease after Treatment with Prednisolone. *Case Reports in Obstetrics and Gynecology*, **2020**, 2020, 8862651	0.8	
90	Model-Agnostic Method for Thoracic Wall Segmentation in Fetal Ultrasound Videos. *Biomolecules*, **2020**, 10,	5.9	13
89	Distribution of PAPP-A and total hCG between 11 and 13 weeks of gestation in Japanese pregnant women. *Journal of Maternal-Fetal and Neonatal Medicine*, **2020**, 33, 2017-2022	2	
88	Whole-Genome Analysis of Human Papillomavirus Type 16 Prevalent in Japanese Women with or without Cervical Lesions. *Viruses*, **2019**, 11,	6.2	3
87	Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. *Journal of Clinical Medicine*, **2019**, 8,	5.1	8
86	Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. *American Journal of Obstetrics and Gynecology*, **2019**, 221, 650.e1-650.e16	6.4	33
85	Classification of factors involved in nonreportable results of noninvasive prenatal testing (NIPT) and prediction of success rate of second NIPT. *Prenatal Diagnosis*, **2019**, 39, 100-106	3.2	18
84	Within-Host Variations of Human Papillomavirus Reveal APOBEC Signature Mutagenesis in the Viral Genome. *Journal of Virology*, **2018**, 92,	6.6	27
83	Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2018**, 224, 165-169	2.4	11
82	Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration. *Scientific Reports*, **2018**, 8, 11205	4.9	13
81	TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. *BMJ Open*, **2018**, 8, e020948	3	5
80	Current status of non-invasive prenatal testing in Japan. *Journal of Obstetrics and Gynaecology Research*, **2017**, 43, 1245-1255	1.9	26
79	Evaluation of Second-generation HIFU Systems: Less-invasive Fetal Therapy for TRAP Sequence. *The Showa University Journal of Medical Sciences*, **2017**, 29, 241-251	0.1	2
78	Clinical risk factors for poor neonatal outcomes in umbilical cord prolapse. *Journal of Maternal-Fetal and Neonatal Medicine*, **2016**, 29, 1652-6	2	11
77	Nationwide survey for current clinical status of amniocentesis and maternal serum marker test in Japan. *Journal of Human Genetics*, **2016**, 61, 879-884	4.3	3

76	Factors affecting parental decisions to terminate pregnancy in the presence of chromosome abnormalities: a Japanese multicenter study. *Prenatal Diagnosis*, **2016**, 36, 1121-1126	3.2	9
75	Obstetric risk factors for umbilical cord prolapse: a nationwide population-based study in Japan. *Archives of Gynecology and Obstetrics*, **2016**, 294, 467-72	2.5	10
74	Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. *Journal of Human Genetics*, **2016**, 61, 647-52	4.3	40
73	Reference values of focused assessment with sonography for obstetrics (FASO) in low-risk population. *Journal of Maternal-Fetal and Neonatal Medicine*, **2016**, 29, 3449-53	2	
72	A survey on awareness of genetic counseling for non-invasive prenatal testing: the first year experience in Japan. *Journal of Human Genetics*, **2016**, 61, 995-1001	4.3	12
71	The use of balloons for uterine cervical ripening is associated with an increased risk of umbilical cord prolapse: population based questionnaire survey in Japan. *BMC Pregnancy and Childbirth*, **2015**, 15, 4	3.2	15
70	How do the trends in the prenatal diagnosis of aneuploidy change after a non-invasive prenatal test becomes available? A Japanese single center study. *Journal of Medical Ultrasonics (2001)*, **2015**, 42, 195-8	1.4	3
69	Nationwide demonstration project of next-generation sequencing of cell-free DNA in maternal plasma in Japan: 1-year experience. *Prenatal Diagnosis*, **2015**, 35, 331-6	3.2	51
68	Chromosome abnormalities diagnosed in utero: a Japanese study of 28 983 amniotic fluid specimens collected before 22 weeks gestations. *Journal of Human Genetics*, **2015**, 60, 133-7	4.3	11
67	Current Status of the Screening of Chlamydia trachomatis Infection Among Japanese Pregnant Women. *Journal of Clinical Medicine Research*, **2015**, 7, 582-4	2.9	6
66	Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition. *Journal of Obstetrics and Gynaecology Research*, **2014**, 40, 1469-99	1.9	220
65	Maternal smoking and placental expression of a panel of genes related to angiogenesis and oxidative stress in early pregnancy. *Fetal Diagnosis and Therapy*, **2014**, 35, 289-95	2.4	9
64	Circulating mRNA for the PLAC1 gene as a second trimester marker (14-18 weeksRgestation) in the screening for late preeclampsia. *Fetal Diagnosis and Therapy*, **2014**, 36, 196-201	2.4	11
63	Fibrin Adhesive Spray Occlusion using a Laparoscope for Intractable Chylous Ascites: Case Report. *Japanese Journal of Gynecologic and Obstetric Endoscopy*, **2014**, 30, 188-192	0	1
62	Physiological changes in the pattern of placental gene expression early in the first trimester. *Reproductive Sciences*, **2013**, 20, 710-4	3	11
61	Attitudes toward non-invasive prenatal diagnosis among pregnant women and health professionals in Japan. *Prenatal Diagnosis*, **2012**, 32, 674-9	3.2	35
60	Higher circulating mRNA levels of placental specific genes in a patient with placenta accreta. *Prenatal Diagnosis*, **2011**, 31, 827-9	3.2	8
59	Quantitative RT-PCR gene expression analysis of a laser microdissected placenta: an approach to study preeclampsia. *Methods in Molecular Biology*, **2011**, 755, 477-89	1.4	

58	Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. *American Journal of Obstetrics and Gynecology*, **2010**, 203, 575.e1-7	6.4	40
57	Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. *Reproductive Sciences*, **2009**, 16, 857-64	3	28
56	PP13 mRNA expression in trophoblasts from preeclamptic placentas. *Reproductive Sciences*, **2009**, 16, 408-13	3	57
55	Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. *American Journal of Obstetrics and Gynecology*, **2009**, 200, 386.e1-7	6.4	42
54	Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. *Prenatal Diagnosis*, **2009**, 29, 691-6	3.2	36
53	Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening. *Prenatal Diagnosis*, **2009**, 29, 1038-44	3.2	20
52	PP13 mRNA expression in the cellular component of maternal blood as a marker for preeclampsia. *Prenatal Diagnosis*, **2009**, 29, 1231-6	3.2	25
51	Gene expression in chorionic villous samples at 11 weeksR gestation from women destined to develop preeclampsia. *Prenatal Diagnosis*, **2008**, 28, 956-61	3.2	74
50	Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. *American Journal of Obstetrics and Gynecology*, **2008**, 198, 124.e1-7	6.4	29
49	Detection and quantification of fetal DNA in maternal plasma by using LightCycler technology. *Methods in Molecular Biology*, **2008**, 444, 231-8	1.4	7
48	Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. *Prenatal Diagnosis*, **2007**, 27, 772-7	3.2	62
47	Development of noninvasive fetal DNA diagnosis from nucleated erythrocytes circulating in maternal blood. *Prenatal Diagnosis*, **2007**, 27, 846-8	3.2	15
46	Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeksR gestation. *Prenatal Diagnosis*, **2007**, 27, 1005-10	3.2	26
45	Recent advances in non-invasive prenatal DNA diagnosis through analysis of maternal blood. *Journal of Obstetrics and Gynaecology Research*, **2007**, 33, 747-64		24
44	Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with preeclampsia. *Clinical Chemistry*, **2007**, 53, 399-404	5.5	49
43	Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women. *Obstetrics and Gynecology*, **2007**, 110, 1130-6	4.9	27
42	The role of p53 mutation in the carcinomas arising from endometriosis. *International Journal of Gynecological Pathology*, **2007**, 26, 345-51	3.2	36
41	Clinical potential for noninvasive prenatal diagnosis through detection of fetal cells in maternal blood. *Taiwanese Journal of Obstetrics and Gynecology*, **2006**, 45, 10-20	1.6	11

40	Enrichment of NRBC in maternal blood: a more feasible method for noninvasive prenatal diagnosis. *Prenatal Diagnosis*, **2006**, 26, 545-7	3.2	21
39	Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls. *Prenatal Diagnosis*, **2006**, 26, 1115-20	3.2	43
38	Cell-Free Fetal DNA in Plasma of Pregnant Women: Clinical Potential and Origin. *Taiwanese Journal of Obstetrics and Gynecology*, **2005**, 44, 116-122	1.6	6
37	Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. *International Journal of Gynecological Pathology*, **2005**, 24, 369-76	3.2	16
36	Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. *Prenatal Diagnosis*, **2005**, 25, 604-7	3.2	40
35	Lower maternal PLAC1 mRNA in pregnancies complicated with vaginal bleeding (threatened abortion . *Clinical Chemistry*, **2005**, 51, 224-7	5.5	23
34	Rapid clearance of mRNA for PLAC1 gene in maternal blood after delivery. *Fetal Diagnosis and Therapy*, **2005**, 20, 27-30	2.4	13
33	Fragmentation of Fetal DNA in Maternal Plasma and Urine. *The Showa University Journal of Medical Sciences*, **2005**, 17, 81-87	0.1	
32	Proteinuria and hypertension are independent factors affecting fetal DNA values: a retrospective analysis of affected and unaffected patients. *Clinical Chemistry*, **2004**, 50, 221-4	5.5	28
31	Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes. *Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan*, **2004**, 37, 97-100		20
30	K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. *Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan*, **2004**, 37, 188-92		38
29	Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. *Prenatal Diagnosis*, **2004**, 24, 83-6	3.2	54
28	Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. *Prenatal Diagnosis*, **2004**, 24, 293-7	3.2	25
27	beta-globin DNA in maternal plasma as a molecular marker of pre-eclampsia. *Prenatal Diagnosis*, **2004**, 24, 697-700	3.2	30
26	Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. *Prenatal Diagnosis*, **2004**, 24, 722-6	3.2	52
25	Relationship between Malignant Transformation of Endometriosis and Genetic Alterations of K-ras and Microsatellite Instability. *The Showa University Journal of Medical Sciences*, **2004**, 16, 47-54	0.1	
24	Placenta increta: Postpartum monitoring of plasma cell-free fetal DNA. *Clinical Chemistry*, **2003**, 49, 1540-1	5.5	30
23	Evaluation of bidirectional transfer of plasma DNA through placenta. *Human Genetics*, **2003**, 113, 307-10	6.3	42

22	Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. *American Journal of Obstetrics and Gynecology*, **2003**, 188, 480-4	6.4	104
21	p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. *Gynecologic Oncology*, **2003**, 88, 318-25	4.9	86
20	Relationship between severity of hyperemesis gravidarum and fetal DNA concentration in maternal plasma. *Clinical Chemistry*, **2003**, 49, 1667-9	5.5	44
19	Testing normality of fetal DNA concentration in maternal plasma at 10-12 completed weeksR gestation: a preliminary approach to a new marker for genetic screening. *Prenatal Diagnosis*, **2002**, 22, 148-52	3.2	24
18	Fate of Fetal Nucleated Erythrocytes Circulating in Maternal Blood: Apoptosis Is Induced by Maternal Oxygen Concentration. *Clinical Chemistry*, **2002**, 48, 1618-1620	5.5	17
17	Increased Cell-free Fetal DNA in Plasma of Two Women with Invasive Placenta. *Clinical Chemistry*, **2002**, 48, 353-354	5.5	112
16	Increased cell-free fetal DNA in plasma of two women with invasive placenta. *Clinical Chemistry*, **2002**, 48, 353-4	5.5	21
15	Fate of fetal nucleated erythrocytes circulating in maternal blood: apoptosis is induced by maternal oxygen concentration. *Clinical Chemistry*, **2002**, 48, 1618-20	5.5	6
14	Accuracy of Fetal Gender Determination by Analysis of DNA in Maternal Plasma. *Clinical Chemistry*, **2001**, 47, 1856-1858	5.5	113
13	Cell-free Fetal DNA Is Increased in Plasma of Women with Hyperemesis Gravidarum. *Clinical Chemistry*, **2001**, 47, 2164-2165	5.5	77
12	Comparison of fetal cell recovery from maternal blood using a high density gradient for the initial separation step: 1.090 versus 1.119 g/ml. *Prenatal Diagnosis*, **2000**, 20, 281-6	3.2	32
11	Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. *Prenatal Diagnosis*, **2000**, 20, 886-9	3.2	89
10	Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. *Lancet, The*, **2000**, 356, 1170	40	207
9	Female fetal cells in maternal blood: use of DNA polymorphisms to prove origin. *Human Genetics*, **2000**, 107, 28-32	6.3	34
8	Female fetal cells in maternal blood: use of DNA polymorphisms to prove origin **2000**, 107, 28		10
7	Fetal cell recycling: diagnosis of gender and RhD genotype in the same fetal cell retrieved from maternal blood. *American Journal of Obstetrics and Gynecology*, **1999**, 181, 1237-42	6.4	29
6	Improvement of fetal cell recovery from maternal blood: suitable density gradient for FACS separation. *Fetal Diagnosis and Therapy*, **1999**, 14, 229-33	2.4	33
5	Prenatal diagnosis of ornithine transcarbamylase deficiency by using a single nucleated erythrocyte from maternal blood. *Human Genetics*, **1998**, 102, 611-5	6.3	31

4	3Beta-hydroxysteroid dehydrogenase activity in human osteoblast-like cells. *Endocrine Journal*, **1997**, 44, 847-53	2.9	14
3	A study of gamma-aminobutyric acid (GABA) in amniotic fluid. *Journal of Obstetrics and Gynaecology Research*, **1997**, 23, 471-7		2
2	Prenatal diagnosis of the fetal RhD blood type using a single fetal nucleated erythrocyte from maternal blood. *Obstetrics and Gynecology*, **1996**, 87, 501-5	4.9	57
1	A study of monoamine oxidase activity in fetal membranes. *Acta Obstetricia Et Gynecologica Scandinavica*, **1996**, 75, 423-7	3.8	4